Back

Economic evaluation of rivaroxaban versus acenocoumarol in the prevention of stroke in patients with non-valvular atrial fibrillation in spain

28 August 2016 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Stroke and more Stroke ESC Premium Access ESC Congress 2016

About the speaker

Photo
Mrs Belen Espinos

Barcelona (Spain)

18 More presentations in this session

Presentation thumbnail
Professor A. Rosengren (Gothenburg, SE)
Abstract Slides
Presentation thumbnail
Doctor K. Dimitriadis (Athens, GR)
Abstract
Presentation thumbnail
Doctor M. Oguri (Kasugai, JP)
Abstract Slides
Presentation thumbnail
Doctor C. Park (Seoul, KR)
Abstract Slides
Presentation thumbnail
Doctor N. Ozier-Lafontaine (Fort de France, MQ)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Stroke and more

The Event

Event poster

ESC Congress 2016

28 August 2016 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Cost differences between oral anticoagulation therapies in atrial fibrillation patients
1 September 2024
thumbnail
Congress Presentation
Incidence of cardiovascular events in patients with atrial fibrillation anticoagulated with rivaroxaban after 2.5 years of follow-up: not all is stroke or bleeding
27 August 2021
thumbnail
Congress Presentation
Atrial fibrillation burden of illness: epidemiology and annual economic impact
23 April 2021
thumbnail
Webinar
Are NOACs already outdated? New trends in anticoagulation therapy
12 December 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources